2013
Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C. Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal Of The National Cancer Institute 2013, 105: 1332-1334. PMID: 23958736, PMCID: PMC3888280, DOI: 10.1093/jnci/djt204.Peer-Reviewed Original ResearchConceptsCYP2D6 genotypeCYP2D6 metabolic phenotypeBreast cancer patientsMetabolic phenotypeAnti-estrogen tamoxifenCancer clinical trialsCancer patientsClinical trialsTumor alterationsGermline DNAConflicting resultsPatientsTumorsTissue sourcesGenotype association studiesConcordanceGenotypesPhenotypeAssociation studiesFFPETTamoxifenEndoxifenWBCCYP2D6Trials
2008
Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Punglia R, Burstein H, Winer E, Weeks J. Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. Journal Of The National Cancer Institute 2008, 100: 1332-1333. DOI: 10.1093/jnci/djn270.Peer-Reviewed Original ResearchDifferences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection
MA Y, PEAKMAN M, LOBO-YEO A, WEN L, LENZI M, GÄKEN J, FARZANEH F, MIELI-VERGANI G, BIANCHI F, VERGANI D. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clinical & Experimental Immunology 2008, 97: 94-99. PMID: 8033426, PMCID: PMC1534799, DOI: 10.1111/j.1365-2249.1994.tb06585.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibody SpecificityAutoantibodiesAutoantigensAutoimmune DiseasesB-LymphocytesChildChild, PreschoolCytochrome P-450 CYP2D6Cytochrome P-450 Enzyme SystemFemaleHepatitisHepatitis CHepatitis, ChronicHumansInfantMaleMiddle AgedMixed Function OxygenasesRecombinant Fusion ProteinsConceptsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionLKM-1 antibodiesAutoimmune hepatitisC virus infectionLKM-1HCV infectionVirus infectionCytochrome P4502D6Liver kidney microsomal antibodiesClassical autoimmune hepatitisKidney microsomal antibodyChronic HCV infectionLymphoblastoid B cell linesMicrosomal antibodiesPositive patientsLiver diseaseB cell linesHCVPatientsImmune recognitionMolecular mimicryRecombinant CYP2D6Western blotCYP2D6
2005
Bench to Bedside: Pharmacogenomics, Adverse Drug Interactions, and the Cytochrome P450 System
Sikka R, Magauran B, Ulrich A, Shannon M. Bench to Bedside: Pharmacogenomics, Adverse Drug Interactions, and the Cytochrome P450 System. Academic Emergency Medicine 2005, 12: 1227-1235. PMID: 16282513, DOI: 10.1197/j.aem.2005.06.027.Peer-Reviewed Original ResearchConceptsAdverse drug interactionsDrug interactionsCytochrome P450 familyCytochrome P450 systemPreventable medical errorsClinical effectsTherapeutic implicationsHealth careP450 systemPharmaceutical agentsMedical errorsCytochrome P450P450 familyPharmacogenomicsCYP2C19PopulationBasic biochemistryCYP2E1CYP2C9CYP3A4CYP2D6PhysiciansCYP1A2BedsideCare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply